Smith, Moore & Co’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
Other funds holding IMDX
AIC
Smith, Moore & Co's IMDX Position: Q3 2026 in Review
Smith, Moore & Co opened a new position in Insight Molecular Diagnostics (IMDX) in Q3 2026: 10,000 shares worth $35.9K. The stake represents ﹤0.01% of the portfolio and ranks #582 among its holdings.
40 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.
- Smith, Moore & Co held 10,000 shares of Insight Molecular Diagnostics worth $35.9K as of Q3 2026.
- Insight Molecular Diagnostics was a new Smith, Moore & Co position in Q3 2026.
- Insight Molecular Diagnostics made up ﹤0.01% of Smith, Moore & Co's portfolio in Q3 2026, its #582 holding.
- 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.
Based on Smith, Moore & Co's 13F filing for Q3 2026, filed 12 Nov 2026.